secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001297184-26-000031
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q1 2026 GAAP net income drops 75% to $6.4M; adjusted EPS falls to $0.42
--------------------------------------------------------------------------------

- Net revenues flat at $171.2M vs $170.5M YoY.
- GAAP net income $6.4M ($0.14 diluted EPS) vs $25.3M ($0.51) in Q1 2025.
- Adjusted non-GAAP net income $19.5M ($0.42 diluted EPS) vs $36.9M ($0.74).
- Launched Ipratropium Bromide HFA; signed license for synthetic corticotropin compound.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718426000031/0001297184-26-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718426000031/amph-20260507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-26-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer